Cat.No. : CSC-RO1125 Host Cell: NCI-H82
| Cat. No. | CSC-RO1125 |
| Description | This cell line is engineered to co-express human CD274 and luciferase reporter gene in NCI-H82 cells. |
| Gene | CD274/Luc |
| Gene Species | Homo sapiens (Human) |
| Host Cell | NCI-H82 |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Application | 1. Studying the interactions between immune cells and cancer cells 2. Studying the mechanisms of resistance to immune checkpoint blockade 3. High-throughput screening 4. Drug target validation |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Researchers investigated the function of CD274 Luc Stable Cell Line in elucidating the regulatory role of lncRNA-NKX2-1-AS1 in cancer-related pathways. They observed higher levels of NKX2-AS1 and NKX2-1 in lung adenocarcinomas, suggesting independent regulation. Loss-and-gain of function experiments revealed NKX2-1-AS1's role in controlling genes in trans, including PD-L1. NKX2-1-AS1 negatively regulated CD274/PD-L1 expression and interfered with NKX2-1 protein binding to the CD274-promoter. This sheds light on NKX2-1-AS1's potential role in limiting lung carcinoma cell motility and immune evasion, providing insights into lung epithelial cell tumorigenic capabilities.
Figure 1. A 1.1 kb segment preceding the human CD274 gene's transcription start site was synthesized and inserted into the pGL3-basic plasmid (Promega) to create CD274-Luc. The regulatory effect of NKX2-1-AS1 on CD274 expression in A549 cells was investigated using the CD274 Luc Stable Cell Line. NKX2-1 protein binding to the CD274 promoter was assessed via ChIP-qPCR analysis. Overexpression of NKX2-1-AS1 resulted in a dose-dependent reduction in CD274 expression, indicating its potential role as a regulator of the immune checkpoint CD274. (Kathuria H, et al., 2018)
A: CHO-K1 cells were likely chosen for their robust growth and protein expression capabilities, allowing for efficient expression of TREM1-TYROBP and investigation of its role in immune regulation, inflammation, and disease pathogenesis.
A: Stability was likely assessed through methods such as flow cytometry, immunoblotting, or functional assays measuring TREM1-TYROBP-mediated signaling, with continuous selection pressure applied.
A: Characterization may involve analysis of TREM1-TYROBP membrane localization, interaction with binding partners such as TYROBP/DAP12, downstream signaling pathways, and functional implications in immune cell activation, cytokine production, or inflammatory responses.
A: Quality control likely included confirmation of TREM1-TYROBP expression levels, validation of its functional activity, assessment of off-target effects, and validation of phenotypic changes associated with TREM1-TYROBP modulation.
A: Comparative analysis with primary immune cells or in vivo models helps validate the relevance of TREM1-TYROBP expression in inflammatory responses, sepsis, autoimmune disorders, and its potential as a target for immunomodulatory therapies.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Consistent luciferase activity! The Human CD274/Luc Stable Cell Line in NCI-H82 cells ensures reliable CD274 expression and luciferase reporter activity, facilitating precise measurements in cancer immunotherapy research.
Facilitating advanced studies! With stable CD274 expression and luciferase reporter, I can investigate PD-L1 signaling pathways and immunotherapy responses with confidence, advancing scientific understanding.
Reliable performance! This cell line surpasses expectations, providing a robust platform for studying CD274-targeted therapies and immune checkpoint blockade approaches.
Enhancing research efficiency! Its stable expression of CD274 and luciferase simplifies experimental workflows, enabling streamlined data analysis and accelerating discoveries.
An invaluable resource! The Human CD274/Luc Stable Cell Line has significantly contributed to my research, offering valuable insights into CD274-mediated immune evasion mechanisms and therapeutic strategies for cancer treatment.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
